Drug intelligence / Profile preview

Cd-ISTAb

Development stage: Unknown
Lead developer: Integrated BioTherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Cd-ISTAb is a monoclonal antibody developed by Integrated Biotherapeutics for the treatment of *Clostridium difficile* infection. It acts as an inhibitor of Toxin A (toxA) and Toxin B (toxB), which are key virulence factors produced by *Clostridium difficile*. By neutralizing these toxins, Cd-ISTAb aims to prevent or mitigate the symptoms and complications associated with *C. difficile* infection, a significant cause of infectious disease morbidity in healthcare settings[1][2].

Targets

TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)

Beyond the preview

Go deeper on Cd-ISTAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cd-ISTAb.

Explore the full profile